Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals, Inc. Stock Is Jumping 12.4% Today

By Keith Speights - Aug 8, 2018 at 12:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A Q2 update about the progress of a late-stage clinical study provides a nice boost to the clinical-stage biotech stock.

What happened

Shares of Inovio Pharmaceuticals, Inc. (INO -4.57%) were up 12.4% as of 11:32 a.m. EDT on Wednesday. The stock's jump stemmed from the biotech's announcement of its second-quarter results after the market closed on Tuesday.

So what

Inovio is a clinical-stage biotech with no products on the market. The reality is that its financial results in a given quarter don't mean a lot. So why did the stock enjoy such a nice bounce?

Gloved hands hold test tubes. Hand of person in blazer holds white cell phone displaying a question mark.

Image source: Getty Images.

Investors were likely excited to hear about progress for Inovio's phase 3 Reveal 1 clinical study evaluating VGX-3100 in treating cervical dysplasia caused by the human papillomavirus (HPV). The company stated that enrollment is on track in this study, with 70 sites in 16 countries actively recruiting patients.

VGX-3100 presents Inovio's best chance for advancing a product to commercialization. It's the only pipeline candidate that Inovio currently has in phase 3 testing. Once the Reveal 1 study reaches full enrollment, Inovio plans to immediately begin its Reveal 2 confirmatory study. 

If all goes well with these studies and Inovio ultimately wins regulatory approval for VGX-3100, it could have a big winner on its hands. Market research firm EvaluatePharma projects that the DNA immunotherapy could be one of the most valuable experimental vaccines in the biopharmaceutical industry.  

Now what

It's great that Inovio is moving along nicely with its late-stage study of VGX-3100. The problem is that the biotech's studies of the immunotherapy won't fully wrap up until 2020. In the meantime, Inovio doesn't have steady revenue coming in the door and continues to burn through cash.

Inovio does have a remarkably deep pipeline for a clinical-stage biotech. However, these programs are either in phase 1 or phase 2 testing. The only revenue they might generate for Inovio is through collaborations. Unfortunately, this revenue won't be nearly enough to fund the company's operations.

This means that sooner or later Inovio will probably have to raise additional cash through a stock offering. When that happens, the biotech's share price is likely to drop -- just as it has in the past.

Inovio could be a big winner over the long run if VGX-3100 or its other pipeline candidates are successful. But there's no certainty that success will come. Inovio stock will probably be very volatile for a long time to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.88 (-4.57%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.